tiprankstipranks
Akari Therapeutics (AKTX)
NASDAQ:AKTX

Akari Therapeutics (AKTX) Income Statement

273 Followers

Akari Therapeutics Income Statement

Last quarter (Q ), Akari Therapeutics's total revenue was $―, a decrease of ― from the same quarter last year. In Q, Akari Therapeutics's net income was $―. See Akari Therapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 23Dec 22Dec 21Dec 20Dec 19
Total Revenue
----$ 0.00$ 0.00
Cost of Revenue
------
Gross Profit
------
Operating Expense
$ 16.93M$ 16.81M$ 23.23M$ 17.24M$ 17.98M$ 16.96M
Operating Income
$ -16.93M$ -16.81M$ -23.23M$ -17.24M$ -17.98M$ -16.96M
Net Non Operating Interest Income Expense
$ 12.30K$ 82.00K$ 45.94K$ 10.60K$ 13.62K$ 5.53K
Other Income Expense
$ 275.49K$ -6.58M$ -4.98M-$ 885.74K$ 111.39K
Pretax Income
$ -16.64M$ -10.01M$ -17.75M$ -17.42M$ -17.08M$ -16.85M
Tax Provision
--$ -4.20K$ -60.37K$ -2.86M$ -2.99M
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
$ -16.64M$ -10.01M$ -17.75M$ -17.42M$ -17.08M$ -16.85M
Basic EPS
$ -0.32---$ -1.00$ -1.00
Diluted EPS
$ -0.32---$ -1.00$ -1.00
Basic Average Shares
$ 160.58M$ 9.79B$ 6.24B$ 4.29B$ 31.59M$ 18.31M
Diluted Average Shares
$ 160.58M$ 9.79B$ 6.24B$ 4.29B$ 31.59M$ 18.31M
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
------
Total Expenses
$ 16.93M$ 16.81M$ 23.23M$ 17.24M$ 17.98M$ 16.96M
Net Income From Continuing And Discontinued Operation
$ -16.64M$ -10.01M$ -17.75M$ -17.42M$ -17.08M$ -16.85M
Normalized Income
$ -16.95M$ -7.91M--$ -17.99M$ -16.98M
Interest Expense
------
EBIT
$ -16.93M$ -10.01M$ -17.75M$ -17.42M$ -17.98M$ -16.96M
EBITDA
$ -16.93M$ -10.00M$ -17.74M$ -17.42M$ -17.97M$ -16.94M
Currency in USD

Akari Therapeutics Earnings and Revenue History

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis